Regulatory mechanisms of PD-1/PD-L1 in cancers

Xin Lin,Kuan Kang,Pan Chen,Zhaoyang Zeng,Guiyuan Li,Wei Xiong,Mei Yi,Bo Xiang

DOI: https://doi.org/10.1186/s12943-024-02023-w

IF: 37.3

2024-05-19

Molecular Cancer

Abstract:Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein 1 (PD-1) and programmed cell death ligands (PD-Ls) are considered to be the major immune checkpoint molecules. The interaction of PD-1 and PD-L1 negatively regulates adaptive immune response mainly by inhibiting the activity of effector T cells while enhancing the function of immunosuppressive regulatory T cells (Tregs), largely contributing to the maintenance of immune homeostasis that prevents dysregulated immunity and harmful immune responses. However, cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in cancer development and progression. Blockade of PD-1/PD-L1 by neutralizing antibodies restores T cells activity and enhances anti-tumor immunity, achieving remarkable success in cancer therapy. Therefore, the regulatory mechanisms of PD-1/PD-L1 in cancers have attracted an increasing attention. This article aims to provide a comprehensive review of the roles of the PD-1/PD-L1 signaling in human autoimmune diseases and cancers. We summarize all aspects of regulatory mechanisms underlying the expression and activity of PD-1 and PD-L1 in cancers, including genetic, epigenetic, post-transcriptional and post-translational regulatory mechanisms. In addition, we further summarize the progress in clinical research on the antitumor effects of targeting PD-1/PD-L1 antibodies alone and in combination with other therapeutic approaches, providing new strategies for finding new tumor markers and developing combined therapeutic approaches.

oncology,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem this paper attempts to address is the mechanism of action and clinical application of the PD-1/PD-L1 signaling pathway in tumor immunity and autoimmune diseases. Specifically, the article aims to comprehensively review the role of the PD-1/PD-L1 signaling pathway in human autoimmune diseases and cancer, and to summarize the regulatory mechanisms of its expression and activity, including genetic, epigenetic, post-transcriptional, and post-translational regulatory mechanisms. Additionally, the article explores the clinical research progress on the anti-tumor effects of antibodies targeting PD-1/PD-L1, as well as the potential for their combined use with other therapeutic methods, thereby providing new strategies for identifying novel tumor markers and developing combination therapy strategies. Through these studies, the paper hopes to provide references for the early diagnosis and personalized treatment of tumor immunotherapy.